Sotera Health Company

Sotera Health Company is a global provider of integrated health solutions, focusing on sterilization services, laboratory testing, and consultancy tailored for the healthcare sector, ensuring safety and compliance for various industries. Sotera Health Company specializes in health solutions through sterilization and lab services. Founded in 1978 in Broadview Heights, US, the company underwent an IPO on November 19, 2020, raising USD 1. 07 bn.

The firm has made a total of 8 deals, including the sale of Nordion's Medical Isotopes Segment in 2018. It operates 48 facilities across 13 countries worldwide, with its headquarters in Broadview Heights. The company's founder history is not disclosed. Sotera Health is a prominent global provider of integrated health solutions, primarily focusing on sterilization services, laboratory testing, and advisory services tailored for the healthcare industry.

Their core product offerings include Sterigenics®, which provides outsourced terminal sterilization and irradiation services, Nordion®, a reliable source of Cobalt-60 supply and services, and Nelson Labs®, recognized for its extensive microbiological and analytical testing capabilities. These services cater to a wide range of clients, including medical device manufacturers, pharmaceutical companies, and food safety sectors, ensuring the integrity and safety of products utilized in healthcare. The company's operational footprint spans 48 facilities across 13 countries, serving diverse geographical markets including North America, Europe, and Asia-Pacific. By upholding rigorous testing and sterilization standards, Sotera Health aims to deliver mission-critical solutions that safeguard global health.

For the year 2024, Sotera Health reported a revenue of USD 1,100,441,000 and an EBITDA of USD 468,501,000. Revenue is generated through various service contracts and partnerships with its clientele, focusing on B2B transactions. The company’s services are critical for maintaining compliance with regulatory standards in the medical and pharmaceutical sectors, further establishing its role as a trusted partner for healthcare stakeholders. Sotera Health aims to leverage its recent IPO to enhance its service offerings and expand its market presence.

The funding will support the launch of new products and services across its existing markets. Specific geographic targets for expansion include Europe and Asia-Pacific regions by the end of 2025, while continuing to innovate with additional lab testing capabilities and advanced sterilization solutions.